Female sexual dysfunction: A case study of disease mongering and activist resistance
2006

Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance

Sample size: 3000 publication Evidence: moderate

Author Information

Author(s): Leonore Tiefer

Primary Institution: New York University School of Medicine

Hypothesis

The creation and promotion of female sexual dysfunction (FSD) exemplifies disease mongering by the pharmaceutical industry.

Conclusion

The medicalization of women's sexual problems has been driven by the pharmaceutical industry, leading to a widespread perception of sexual inadequacy.

Supporting Evidence

  • The pharmaceutical industry has aggressively marketed drugs for female sexual dysfunction.
  • Activist groups have emerged to challenge the medicalization of women's sexual problems.
  • Historical context shows a shift in societal attitudes towards women's sexuality over the 20th century.

Takeaway

This study shows how companies try to convince women they have a problem with their sex life, even when they might not, and how some people are fighting back against this idea.

Methodology

The essay examines historical and cultural factors contributing to the medicalization of female sexual dysfunction.

Potential Biases

Potential bias from pharmaceutical industry influence on research and media representation.

Limitations

The study primarily focuses on the historical context and does not provide new empirical data.

Participant Demographics

Women with female sexual arousal disorder, with a sample size of about 3000.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0030178

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication